MinervaX appoints Lidia Oostvogels as CMO

Privately held Danish biotechnology company MinervaX has appointed Lidia Oostvogels as chief medical officer, bringing a wealth of experience in vaccine development with more than 25 years’ experience in clinical development.

Before joining MinervaX, she was senior vice president, area head, infectious diseases and senior vice president, clinical development, for prophylactic vaccines at CureVac AG. Ms Oostvogels has worked for UK pharma major GSK (LSE: GSK) for more than 12 years, where she was director of vaccine discovery and development, clinical, focused on influenza and Zoster.

Prior to GSK, she spent nine years with Germany’s Boehringer Ingelheim in a clinical development role. She gained her medical doctor qualification from Ghent University in Belgium. Ms Oostvogels’ experience will be instrumental as MinervaX progresses its GBS vaccine towards phase III clinical development.